Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19
The dysfunctional effects of the coronavirus disease 2019 (COVID-19) infection on the nervous system are established. The manifestation of neuropsychiatric symptoms during and after infection is influenced by the neuroinvasive and neurotrophic properties of SARS-CoV-2 as well as strong inflammation...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/11/10/1056 |
| _version_ | 1797514128493903872 |
|---|---|
| author | Eliza Dąbrowska Beata Galińska-Skok Napoleon Waszkiewicz |
| author_facet | Eliza Dąbrowska Beata Galińska-Skok Napoleon Waszkiewicz |
| author_sort | Eliza Dąbrowska |
| collection | DOAJ |
| description | The dysfunctional effects of the coronavirus disease 2019 (COVID-19) infection on the nervous system are established. The manifestation of neuropsychiatric symptoms during and after infection is influenced by the neuroinvasive and neurotrophic properties of SARS-CoV-2 as well as strong inflammation characterised by a specific “cytokine storm”. Research suggests that a strong immune response to a SARS-CoV-2 infection and psychological stressors related to the pandemic may cause chronic inflammatory processes in the body with elevated levels of inflammatory markers contributing to the intensification of neurodegenerative processes. It is suggested that neuroinflammation and associated central nervous system changes may significantly contribute to the etiopathogenesis of depressive disorders. In addition, symptoms after a COVID-19 infection may persist for up to several weeks after an acute infection as a post-COVID-19 syndrome. Moreover, previous knowledge indicates that among SSRI (selective serotonin reuptake inhibitor) group antidepressants, fluoxetine is a promising drug against COVID-19. In conclusion, further research, observation and broadening of the knowledge of the pathomechanism of a SARS-CoV-2 infection and the impact on potential complications are necessary. It is essential to continue research in order to assess the long-term neuropsychiatric effects in COVID-19 patients and to find new therapeutic strategies. |
| first_indexed | 2024-03-10T06:27:15Z |
| format | Article |
| id | doaj.art-ba2c4d1cb6094f2ab56108b519741d8f |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T06:27:15Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-ba2c4d1cb6094f2ab56108b519741d8f2023-11-22T18:52:51ZengMDPI AGLife2075-17292021-10-011110105610.3390/life11101056Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19Eliza Dąbrowska0Beata Galińska-Skok1Napoleon Waszkiewicz2Department of Psychiatry, Medical University of Bialystok, pl. Brodowicza 1, 16-070 Choroszcz, PolandDepartment of Psychiatry, Medical University of Bialystok, pl. Brodowicza 1, 16-070 Choroszcz, PolandDepartment of Psychiatry, Medical University of Bialystok, pl. Brodowicza 1, 16-070 Choroszcz, PolandThe dysfunctional effects of the coronavirus disease 2019 (COVID-19) infection on the nervous system are established. The manifestation of neuropsychiatric symptoms during and after infection is influenced by the neuroinvasive and neurotrophic properties of SARS-CoV-2 as well as strong inflammation characterised by a specific “cytokine storm”. Research suggests that a strong immune response to a SARS-CoV-2 infection and psychological stressors related to the pandemic may cause chronic inflammatory processes in the body with elevated levels of inflammatory markers contributing to the intensification of neurodegenerative processes. It is suggested that neuroinflammation and associated central nervous system changes may significantly contribute to the etiopathogenesis of depressive disorders. In addition, symptoms after a COVID-19 infection may persist for up to several weeks after an acute infection as a post-COVID-19 syndrome. Moreover, previous knowledge indicates that among SSRI (selective serotonin reuptake inhibitor) group antidepressants, fluoxetine is a promising drug against COVID-19. In conclusion, further research, observation and broadening of the knowledge of the pathomechanism of a SARS-CoV-2 infection and the impact on potential complications are necessary. It is essential to continue research in order to assess the long-term neuropsychiatric effects in COVID-19 patients and to find new therapeutic strategies.https://www.mdpi.com/2075-1729/11/10/1056COVID-19SARS-CoV-2neuroinflammationdepressive disordersdepressionneurocognitive disorders |
| spellingShingle | Eliza Dąbrowska Beata Galińska-Skok Napoleon Waszkiewicz Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19 Life COVID-19 SARS-CoV-2 neuroinflammation depressive disorders depression neurocognitive disorders |
| title | Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19 |
| title_full | Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19 |
| title_fullStr | Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19 |
| title_full_unstemmed | Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19 |
| title_short | Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19 |
| title_sort | depressive and neurocognitive disorders in the context of the inflammatory background of covid 19 |
| topic | COVID-19 SARS-CoV-2 neuroinflammation depressive disorders depression neurocognitive disorders |
| url | https://www.mdpi.com/2075-1729/11/10/1056 |
| work_keys_str_mv | AT elizadabrowska depressiveandneurocognitivedisordersinthecontextoftheinflammatorybackgroundofcovid19 AT beatagalinskaskok depressiveandneurocognitivedisordersinthecontextoftheinflammatorybackgroundofcovid19 AT napoleonwaszkiewicz depressiveandneurocognitivedisordersinthecontextoftheinflammatorybackgroundofcovid19 |